Composition for anti-obesity and oral composition

Abstract

An object of the present invention is to provide an anti-obesity composition and an oral composition that can promote the gene expression of proteins such as PGC1α and UCP1 related to brown adipocytes or their energy-consuming effects, and have the effect of promoting energy-consuming effects in brown adipocytes. The composition of the present invention contains irigenin and pinitol. The irigenin is preferably irigenin. The composition of the present invention is preferably used as an anti-obesity composition and an oral composition.

Description

Technical Field

[0001] The present invention relates to compositions for anti-obesity, body fat reduction, fat metabolism promotion, fat burning promotion, heat generation promotion, energy consumption promotion, and oral use. In addition, the present invention relates to the use of tectorigenin and pinitol in the manufacture of functional foods for obesity improvement, body fat reduction, fat metabolism promotion, fat burning promotion, heat generation promotion, or energy consumption promotion. In addition, the present invention also relates to a method for obesity improvement, body fat reduction, fat metabolism promotion, fat burning promotion, heat generation promotion, or energy consumption promotion using a composition containing tectorigenin and pinitol. Background Art

[0002] Obesity is closely related to the consumption of body fat, and the consumption of fat is specifically formed by the following mechanism.

[0003] When fat mobilizing hormones such as norepinephrine are secreted, in white adipocytes distributed in the subcutaneous or visceral regions, hormone-sensitive lipase, which is a fat-decomposing enzyme, is activated, and the triglycerides (neutral fats) accumulated in white adipocytes are decomposed into glycerol and free fatty acids, which are then released into the blood. The free fatty acids released into the blood are taken up into the mitochondria of brown adipocytes distributed near the collarbone, around the chest, shoulders, etc., and are consumed as heat. In this way, white adipocytes play a role in accumulating excess energy in the body in the form of fat, while brown adipocytes play a role in burning fat to generate heat.

[0004] As one of the candidate molecules involved in the autonomic regulation of energy consumption, UCP1 and PGC1α are known.

[0005] UCP has the function of uncoupling the oxidative phosphorylation reaction in the inner mitochondrial membrane and dissipating energy in the form of heat. Regarding UCP1, which is the most representative of brown adipocyte fat, the following facts are known: 1. The function of UCP1 is reduced in obese animals; 2. UCP1 increases in animals that do not become obese even when eating a lot; 3. Mice in which the gene expression of UCP1 is artificially reduced become fat, and mice with high expression become thin, etc. In addition, PGC1α is known to have the effect of activating UCP1 and promoting mitochondrial hyperplasia through stimulation of β-adrenergic receptors in brown adipocytes (Non-Patent Document 1).

[0006] Therefore, if UCP1 and PGC1α are activated, an anti-obesity effect can be expected, and thus drugs and foods that are excellent in activating UCP1 and PGC1α have been explored.

[0007] On the other hand, conventionally, as technologies aiming at reducing white adipose tissue such as subcutaneous fat, various anti-obesity agents are known, including Patent Document 1.

[0008] Prior Art Documents

[0009] Patent Documents

[0010] Patent Document 1: Japanese Unexamined Patent Application Publication No. 2017-171654

[0011] Patent Document 2: Japanese Unexamined Patent Application Publication No. 2009-196931

[0012] Non-Patent Documents

[0013] Non-Patent Document 1: Proceedings of the 124th Symposium of the Japanese Medical Association, "Science of Obesity", The Japanese Medical Association, 2003, pp. 62-70 Summary of the Invention

[0014] The action of consuming energy such as fatty acids in brown adipocytes to generate heat (hereinafter also referred to as "energy-consuming action") is important for lipid metabolism. However, if this action can be activated, it is expected that more fat in the body can be converted into heat and a more effective anti-obesity effect can be obtained.

[0015] However, in the above-mentioned prior arts, no study has been conducted on promoting the energy-consuming action in brown adipocytes.

[0016] In addition, the present inventors conducted research and found that conventional anti-obesity agents that are considered to be able to separately reduce white adipose tissue are hardly sufficient in promoting the energy-consuming action occurring in brown adipocytes.

[0017] The present inventors conducted in-depth research on the composition of a composition capable of promoting the energy-consuming action in brown adipocytes by studying the gene expression of proteins such as PGC1α and UCP1 related to the energy-consuming action in brown adipocytes. As a result, it was found that, surprisingly, by combining specific components, the expression of these genes can be promoted, and an excellent effect of promoting the above-mentioned energy consumption can be obtained.

[0018] The present invention has been completed based on the above-mentioned recognition, and provides an anti-obesity composition containing irigenin and pinitol.

[0019] The present invention provides a composition for reducing body fat or promoting fat metabolism, containing irigenin and pinitol.

[0020] The present invention provides a composition for promoting fat burning, promoting heat generation, or promoting energy consumption, containing irigenin and pinitol.

[0021] In addition, the present invention also provides an oral composition containing irigenin and pinitol.

[0022] In addition, the present invention also provides the use of irigenin and pinitol in the manufacture of functional foods for improving obesity, reducing body fat, promoting fat metabolism, promoting fat burning, promoting heat production or promoting energy consumption.

[0023] In addition, the present invention also provides a method for improving obesity, reducing body fat, promoting fat metabolism, promoting fat burning, promoting heat production or promoting energy consumption, which uses a composition containing irigenin and pinitol.

[0024] Advantages of the Invention

[0025] According to the present invention, it is possible to provide a useful oral composition containing a composition containing irigenin and pinitol. In particular, it is possible to provide an effective anti-obesity composition, a body fat reduction composition, a fat metabolism promotion composition, a fat burning promotion composition, a heat production promotion composition, and an energy consumption promotion composition having the effect of promoting the gene expression of proteins such as PGC1α and UCP1 related to the energy consumption function in brown adipocytes and promoting the energy consumption function in brown adipocytes. In addition, it is also possible to provide an oral composition having the effect of promoting the energy consumption function in brown adipocytes through the effect of promoting the gene expression of the above-mentioned PGC1α and UCP1, and being effective in each of the functions of anti-obesity, body fat reduction, fat metabolism promotion, fat burning promotion, heat production promotion, and energy consumption promotion. In addition, according to the present invention, it is also possible to provide the use of a composition containing irigenin and pinitol that can promote the gene expression of PGC1α and UCP1, can promote the energy consumption function in brown adipocytes, is effective, and is used for improving obesity, and a method for improving obesity using irigenin and pinitol as active ingredients. Brief Description of the Drawings

[0026] Figure 1 It is a graph showing the expression levels of the PGC1α gene in the examples and comparative examples.

[0027] Figure 2 It is a graph showing the expression levels of the UCP1 gene in the examples and comparative examples. Detailed Description of the Invention

[0028] Hereinafter, embodiments of the present invention will be given to describe the present invention in more detail, but the present invention is not limited to these embodiments. Hereinafter, the anti-obesity composition, body fat reduction composition, fat metabolism promotion composition, fat burning promotion composition, heat production promotion composition, energy consumption promotion composition, and oral composition of the present invention will be collectively referred to as "the composition of the present invention".

[0029] (Irisflorentinoids)

[0030] Irisflorentinoids refer to irisflorentin, the glycosides of irisflorentin, and their derivatives.

[0031] Irisflorentin is a kind of flavonoid existing in plants such as Iridaceae, represented by the molecular formula C 16 H 12 O6, and is sometimes also called 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzofuran-4-one or 6-methoxy-5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzofuran-4-one. In this specification, when simply referred to as irisflorentin, it means the compound in the form of such an aglycone. The chemical formula of irisflorentin is as follows.

[0032]

Chemical Formula 1

[0033]

[0034] The irisflorentin glycosides in the present invention refer to compounds formed by the combination of one or more sugars selected from monosaccharides and / or sugar acids and the above-mentioned irisflorentin. As monosaccharides, pentoses and hexoses are preferred, and more preferably one or more selected from glucose, xylose, mannose, fructose, sorbose, galactose, apiose, and rhamnose, and particularly preferably one or more selected from glucose and xylose. In addition, as sugar acids, uronic acids are preferred, and glucuronic acid and galacturonic acid are particularly preferred. In glycosides, these sugars and / or sugar acids are usually bonded to the hydroxyl groups at the 4'-position and / or 7-position of irisflorentin. In the present invention, glycosides bonded to the hydroxyl group at the 7-position are preferred. The number of sugars and / or sugar acids in irisflorentin glycosides (also referred to as the number of bonds of sugars and / or sugar acids) can be, for example, 1 or more and 5 or less, preferably 1 or more and 4 or less, and particularly preferably 1 or more and 3 or less. The number of sugars and / or sugar acids refers to the total number of sugars and / or sugar acids. Here, when n sugars are bonded to irisflorentin, it can be the structure of a linker with n sugars bonded, or the total number of sugars bonded to different positions of irisflorentin is n. The same applies when the glycoside contains sugar acids.

[0035] As derivatives of irisflorentin or its glycosides, for example, compounds obtained by substituting one or more hydrogen atoms in irisflorentin or its glycosides with substituents can be mentioned. As such substituents, amino group, sulfonic acid group, alkyl group with 1 or more and 6 or less carbon atoms, alkoxy group with 1 or more and 4 or less carbon atoms, etc. can be mentioned. The number of the above-mentioned substituents in irisflorentinoids is preferably 8 or less, more preferably 4 or less, and most preferably 0.

[0036] In the composition of the present invention, as the irigenin compounds, any one of the above-mentioned irigenin, its glycosides, and their derivatives may be used alone, or a mixture of two or more of them may be used. Particularly in the composition of the present invention, from the perspective of the anti-obesity effect, it is preferred that the irigenin compounds be irigenin and / or its glycosides. From the perspectives of excellent promotion effect on energy consumption in brown adipocytes and ease of acquisition, it is particularly preferred that the composition of the present invention contains irigenin as the irigenin compounds. In the composition of the present invention, the irigenin compounds may be synthetic products or extracted from plants, etc.

[0037] (Pinitol)

[0038] Pinitol is also known as 3-O-methyl-D-chiro-inositol and is a kind of inositol. Pinitol is contained in plants such as carob and clover. In the composition of the present invention, pinitol may be a synthetic product or extracted from plants, etc.

[0039] In the present invention, when the content ratio of the irigenin compounds to pinitol is within a specific range, the gene expressions of PGC1α and UCP1 are excellent, and the energy consumption in brown adipocytes is higher, so it is preferred. In order to improve the energy consumption in brown adipocytes, the content ratio of the irigenin compounds to pinitol by mass is preferably irigenin compounds:pinitol of 1:0.01 or more and 50 or less, more preferably 1:0.05 or more and 30 or less, and particularly preferably 1:0.1 or more and 26 or less. Additionally, for the same reason, when irigenin is used as the irigenin compounds, the content ratio of irigenin to pinitol by mass is preferably irigenin:pinitol of 1:0.01 or more and 50 or less. In particular, due to the excellent energy consumption in brown adipocytes based on the promotion of UCP1 gene expression, it is particularly preferably 1: more than 0.5 and 30 or less, further preferably 1:0.7 or more and 30 or less, and most preferably 1:1 or more and 26 or less.

[0040] The determination of the amount of the irigenin compounds in the composition of the present invention can be carried out by high performance liquid chromatography (HPLC method).

[0041] For example, it can be set as follows: using YMC-Pack ODS AM12S05-2546WT (φ4.6×250mm) manufactured by YMC Co., Ltd., as the liquid medium for the mobile phase, using a mixture of acetonitrile / water / acetic acid (mobile phase A volume ratio = 15:85:0.1, mobile phase B volume ratio = 35:65:0.1), the column temperature is 35°C, and the flow rate is 1.0 ml / minute.

[0042] The gradient conditions can be as shown in Table A below.

[0043] Table A

[0044] Time (minutes) Liquid A (%) Liquid B (%) 0 100 0 50 0 100 55 0 100 57 100 0 70 100 0

[0045] The amount of pinitol in the composition of the present invention can be measured by HPLC.

[0046] For example, the column may be InertSustain NH2 (3 μm, φ3×250 mm) manufactured by GL Sciences Co., Ltd., and the mobile phase may be 1 mM hydrochloric acid / chromatographic acetonitrile (volume ratio = 30 / 70), with a column temperature of 40° C. and a flow rate of 0.5 ml / min.

[0047] The composition of the present invention may contain other commonly used ingredients in addition to tectoriusin and pinitol within the range that does not impair the effects of the present invention. Such ingredients include various excipients, adhesives, glossing agents, lubricants, stabilizers, diluents, extenders, tackifiers, emulsifiers, antioxidants, pH adjusters, colorants, fragrances, additives, etc. The content of other ingredients can be appropriately selected according to the form of the composition of the present invention.

[0048] The composition of the present invention can also be used for any purpose of oral and non-oral use. As non-oral preparations, for example, preparations administered by a method of directly administering to the stomach using a catheter, etc. can be cited. However, the composition of the present invention is preferably made into oral use from the perspective of simply obtaining the effect of the present invention of promoting energy consumption.

[0049] When used as an oral agent, its form includes, for example, tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solid preparations, pills, pastes, creams, capsules, gels, chewables, rods, etc. Among them, tablets, capsules, powders, granules, and liquids are particularly preferred. As examples of oral compositions used in the form of tablets, capsules, powders, granules, and liquids, nutritional supplements can be exemplified; food additives: containerized beverages filled in plastic bottles, cans, bottles, etc.: powdered beverages for dissolving in water (hot water), milk, juice, etc. for drinking. They are preferred from the perspective of being easy to eat and drink when eating, and being able to improve the taste.

[0050] In addition, as a specific example of the oral composition of the present invention, food can be contained as a dietary composition. As food, various foods such as tea bags, bread-snacks, noodles, etc., and cooking products can also be mentioned. As bread-snacks, breads such as staple bread, sweet bread, French bread, English bread, muffins, steamed bread, doughnuts, waffles, etc. can be mentioned; cakes such as butter cakes, sponge cakes, chiffon cakes, pancakes, etc.; frozen desserts such as chocolate, ice cream, ice pops, jelly, cookies, etc. As noodles, udon noodles, plain noodles, etc. can be mentioned. As cooking products, soups such as curry, stew, miso soup, vegetable soup, etc. or their ingredients, seasonings, etc. can be mentioned.

[0051] For the composition of the present invention, it is preferable that the total amount of pinoresinol and iriflavonoids in its solid components is 0.001% by mass or more and 40% by mass or less, from the viewpoints of the promoting effect on energy consumption in brown adipocytes and the ease of continuous oral intake in daily life. More preferably, it contains 0.005% by mass or more and 35% by mass or less, and particularly preferably contains 0.01% by mass or more and 30% by mass or less. It should be noted that the solid component refers to the amount after removing water from the composition.

[0052] In the case of orally ingesting the composition of the present invention, from the viewpoints of the promoting effect on energy consumption in brown adipocytes and the ease of continuous oral intake in daily life, regarding its oral dosage, the total amount of the above-mentioned pinoresinol and iriflavonoids is preferably about 0.1 mg or more and 500 mg or less per day for an adult, and more preferably 0.5 mg or more and 300 mg or less. In addition, the total amount of the above-mentioned pinoresinol and iriflavonoids in one intake amount of the composition of the present invention is preferably about 1 mg or more and 300 mg or less per day for an adult.

[0053] As the utilization modes of the composition of the present invention, specifically, so-called health foods such as pharmaceuticals (including therapeutic cosmetics), general foods, functional foods, specific health foods with efficacy confirmed by a specified institution, and functional display foods can be mentioned. Foods showing efficacy are sometimes collectively referred to as "functional foods".

[0054] As shown in the examples described later, the composition of the present invention can promote energy consumption in brown adipocytes and brown adipose tissue containing the same by promoting the gene expression of multiple proteins associated with energy consumption in brown adipocytes. As such genes, the PGC1α gene and the UCP1 gene can be mentioned.

[0055] The protein PGC1α (PPARγ coactivator 1α) encoded by the PGC1α gene is a protein identified as a transcriptional cofactor that activates transcription based on the nuclear receptor PPARγ. PGC1α activates the transcription factors NRF (nuclear respiratory factor) 1 / NRF2, and NRF promotes the transcription of TFAM (mitochondria transcription factor), thereby activating mitochondrial biogenesis. It is known that mitochondria increase by promoting the gene expression of PGC1α. In addition, PGC1α is a factor that binds to the nuclear receptor of brown adipocytes and is involved in promoting UCP1 gene expression. Therefore, by promoting the gene expression of PGC1α, an energy consumption promoting effect can be expected through the mitochondrial increasing effect and UCP1 gene expression promoting effect in brown adipocytes. The gene of PGC1α is sometimes also denoted as Pgc1α.

[0056] In addition, the UCP1 gene is a gene encoding the molecular uncoupling protein 1 (uncoupling protein 1, UCP1), and is sometimes also denoted as Ucp1. In brown adipocytes, the UCP1 gene is specifically expressed in the mitochondria of these cells. The UCP1 gene has the activity of uncoupling oxidative phosphorylation in mitochondria. If it is activated, the energy generated by the oxidative decomposition of fatty acids or glucose will not be converted into ATP synthesis but directly converted into heat and dissipated. By promoting the expression of the UCP1 gene, it is possible to promote the consumption of fatty acids in brown adipocytes and inhibit or eliminate obesity.

[0057] The effect of the present invention can be an effect of promoting the expression of only one of the PGC1α gene and the UCP1 gene, or an effect of promoting the expression of both the PGC1α gene and the UCP1 gene. In addition to the use of promoting the expression of the PGC1α gene and the UCP1 gene, the composition of the present invention can also be used for various purposes such as promoting fat burning, promoting heat generation, promoting fat metabolism, reducing body fat, and promoting energy consumption. Promoting fat burning refers to the effect of promoting brown adipocytes to convert fatty acids into heat. Promoting heat generation refers to, for example, promoting brown adipocytes to generate heat from neutral fat. The effect of promoting fat metabolism refers to, for example, the effect of transforming adipocytes and adipose tissues that form an obese state into small and normal adipocytes in terms of quality, or the metabolic effect of fatty acids based on brown adipocytes. The effect of reducing body fat refers to, for example, the effect of reducing body fat by converting fatty acids into heat. In addition, the anti-obesity use refers to, for example, the effect of reducing body fat or inhibiting the increase of body fat by promoting the metabolism of fatty acids in brown adipocytes and brown adipose tissues. Promoting energy consumption refers to, for example, the effect of promoting brown adipocytes to consume chemical energy such as fatty acids. These effects are carried out through the activation of PGC1α and UCP1 in brown adipocytes.

[0058] In addition, in the present invention, in addition to the liver and muscles, the locations of brown adipocytes can also include near the collarbone, chest (around the chest), shoulders (scapula and its periphery), etc.

[0059] In addition, when the composition of the present invention is used for purposes such as promoting fat decomposition, anti-obesity, and dieting, it only needs to be distinguishable from other products as a product. For example, the indication of having the function of promoting fat decomposition means the following indication: such as an indication appealing to those who are concerned about obesity, those who are concerned about abdominal circumference, those who are concerned about body weight, those who are concerned about abdominal fat (visceral fat and subcutaneous fat, etc.), that is, an indication appealing to those who are concerned about body fat, or an indication showing that it is helpful for reducing body weight, helpful for reducing abdominal fat (visceral fat and subcutaneous fat, etc.), helpful for reducing waist circumference diameter, supporting the elimination of obesity, supporting dieting, making fat easy to consume, making fat easy to burn, helpful for fat consumption, helpful for fat burning, promoting fat decomposition, making fat easy to decompose, helpful for fat decomposition, etc., that is, an indication helpful for reducing body fat.

[0060] Examples

[0061] Hereinafter, examples will be given to explain the present invention in more detail. However, the scope of the present invention is not limited to these examples. Hereinafter, unless otherwise specified, "%" represents mass%, and "parts" represents mass parts.

[0062] Measurement of the expression level of the PGC1α gene

[0063] [Example 1 and Comparative Examples 1 and 2]

[0064] (1) As the test substance, as irigenin compounds, irigenin (manufactured by Tokyo Chemical Industry Co., Ltd.) was used. In addition, as pinitol, D-pinitol (manufactured by Tokyo Chemical Industry Co., Ltd.) was used.

[0065] (2) As the proliferation medium, a proliferation medium was used; as the differentiation induction medium, a differentiation induction medium was used; as the differentiation maintenance medium, an adipocyte maintenance medium was used. All of the above three media used the medium of the brown adipocyte culture kit F-8 (rat) (manufactured by Cosmo Bio Co., Ltd., derived from interscapular brown adipose tissue). Among them, brown adipocytes derived from interscapular brown adipose tissue are frequently used in studies on the functions of brown adipocytes related to fat burning.

[0066] (3) The differentiation induction medium containing the test substance was prepared as follows. That is, each test substance was dissolved in DMSO and then diluted with the differentiation induction medium so that the final concentration of DMSO reached 0.5 vol%. After that, it was sterilized by filtration. After sterilization, irigenin and pinitol were diluted to the concentrations shown in Table 1 below using the differentiation induction medium containing 0.5 vol% DMSO.

[0067] (4) The differentiation maintenance medium containing the test substance was prepared as follows. That is, each test substance was dissolved in DMSO and then diluted with the differentiation maintenance medium so that the final concentration of DMSO reached 0.5 vol%. After that, it was sterilized by filtration. After sterilization, irigenin and pinitol were diluted to the concentrations shown in Table 1 below using the differentiation maintenance medium containing 0.5 vol% DMSO.

[0068] (5) Using the proliferation medium, rat brown adipocyte precursor cells (manufactured by Cosmo Bio Co., Ltd.) were seeded into a collagen-coated 24-well plate at a density of 3.0×10 4 cells / well at 500 μl / well and cultured in a 37°C, 5 (vol / vol)% CO2 incubator until the cell density reached about 90%.

[0069] (6) After removing the medium, 500 μL / well of the differentiation induction medium containing the test substance was added, and the cells were cultured in a 37°C, 5 (vol / vol)% CO2 incubator for 48 hours to induce differentiation into brown adipocytes.

[0070] (7) After removing the medium, 500 μL / well of the differentiation maintenance medium containing the test substance was added, and the cells were cultured in a 37°C, 5 (vol / vol)% CO2 incubator for 72 hours.

[0071] (8) After removing the culture medium, 500 μL / well of the differentiation maintenance medium containing the test substance was added, and further cultured in a 37 °C, 5 (vol / vol)% CO2 incubator for 72 hours.

[0072] (9) After removing the culture medium, it was washed twice with PBS, RNA was recovered using the RNeasy Mini Kit (manufactured by QIAGEN), and cDNA was synthesized using ReverT raAce(R) qPCR RT Master Mix (manufactured by TOYOBO).

[0073] (10) Using the obtained cDNA as a template, primers for the PGC1α gene (manufactured by QIAGEN) were used, and quantitative real-time PCR was performed using the QuantiNova SYBR Green PCR Kit (manufactured by QIAGEN) to measure the mRNA gene expression level of PGC1α. Regarding the mRNA gene expression levels of PGC1α in Example 1 and Comparative Examples 1 and 2, the relative values when the value of Comparative Example 1 was set to 1 are shown in Figure 1 .

[0074] Table 1

[0075]

[0076] Measurement of UCP1 gene expression

[0077] [Examples 2 to 4 and Comparative Examples 3 and 4]

[0078] Primers for the UCP1 gene (manufactured by QIAGEN) were used instead of Pgc1α. In addition, as the test substance, a test substance having the composition described in Table 2 below was used. The concentration of the test substance in the differentiation induction medium and the differentiation maintenance medium was 50 μM. Except for this point, the mRNA gene expression level of UCP1 was measured in the same manner as in [Example 1 and Comparative Examples 1 and 2]. Regarding the mRNA gene expression levels of UCP1 in Examples 2 to 4 and Comparative Examples 3 and 4, the relative values when the value of Comparative Example 3 was set to 1 are shown in Figure 2 .

[0079] Table 2

[0080]

[0081] As Figure 1 and Figure 2As shown, in the presence of the composition of the present invention that combines irigenin and pinitol, when inducing and maintaining the differentiation of the brown adipocytes, the expression levels of both the PGC1α gene and the UCP1 gene are significantly higher than those when irigenin and pinitol are used separately. In particular, for the UCP1 gene that plays an important role in energy consumption, a synergistic expression promotion effect is exhibited by the combined use of irigenin and pinitol.

[0082] Therefore, it can be known that the composition of the present invention shows an excellent effect of promoting energy consumption in brown adipocytes and is excellent as an anti-obesity agent.

[0083] Manufacture a granule (3000 mg per pack) composed of the following components. By suspending the obtained granule in water and ingesting it twice a day, one pack each time, an excellent anti-obesity effect can be obtained.

[0084] Table 3

[0085]

[0086] Manufacture a granule (2000 mg per pack) composed of the following components. By suspending the obtained granule in hot water and ingesting it three times a day, one pack each time, an excellent anti-obesity effect can be obtained.

[0087] Table 4

[0088]

[0089] Manufacture a tablet (200 mg per tablet) composed of the following components. By ingesting the obtained tablet twice a day, four tablets each time, an excellent anti-obesity effect can be obtained.

[0090] Table 5

[0091]

[0092] Manufacture a tablet (300 mg per tablet) composed of the following components. By ingesting the obtained tablet once a day, five tablets each time, an excellent anti-obesity effect can be obtained.

[0093] Table 6

[0094]

[0095] Manufacture a capsule (300 mg per capsule) composed of the following components. By ingesting the obtained capsule twice a day, two capsules each time, an excellent anti-obesity effect can be obtained.

[0096] Table 7

[0097]

[0098] Industrial Applicability

[0099] The composition of the present invention is expected to have a high anti-obesity effect, and thus has high industrial utility.

Claims

1. Use of a composition containing tectorigenin and pinitol as active ingredients in the manufacture of an anti-obesity agent, wherein, The content ratio of tectorigenin to pinitol is 1:1.3 or more and 25.9 or less by mass ratio, i.e., tectorigenin:pinitol is 1:1.3 or more and 25.9 or less.

2. An oral anti-obesity composition containing tectorigenin and pinitol as active ingredients, and the content ratio of tectorigenin to pinitol is 1:1.3 or more and 25.9 or less by mass ratio, i.e., tectorigenin:pinitol is 1:1.3 or more and 25.9 or less.

3. Use of a composition containing irigenin and pinitol as active ingredients in the manufacture of a functional food for improving obesity, wherein, The content ratio of tectorigenin to pinitol is 1:1.3 or more and 25.9 or less by mass ratio, i.e., tectorigenin:pinitol is 1:1.3 or more and 25.9 or less.

4. A method for promoting body fat reduction, fat metabolism, or fat burning for non-therapeutic purposes, which uses a composition containing tectorigenin and pinitol as active ingredients, wherein, The content ratio of tectorigenin to pinitol is 1:1.3 or more and 25.9 or less by mass ratio, i.e., tectorigenin:pinitol is 1:1.3 or more and 25.9 or less.

Images